Home › NDC Lookup › Ingredients › Olanzapine › 60505-3275-00
⚪image loading
(from DailyMed)

Olanzapine 5 mg Tablet, Orally Disintegrating — NDC 60505-3275-0 (Billing 60505-3275-00)

by Apotex Corp. · 10 BLISTER PACK in 1 CARTON / 10 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK

This is a package of Olanzapine 5 mg Tablet, Orally Disintegrating from Apotex Corp., marketed since Oct 2011 and currently FDA-listed; retail pharmacies pay about $0.3036 per unit (NADAC).

NDC 60505-3275-00
🏷️ FDA NDC (as labeled) 60505-3275-0 billing pads the package segment with a zero
This package
Contains10 tablet, orally disintegrating in 1 blister pack Cost per ea$0.3036 NADAC Per package$30.36 / 100 tablets Pack sizes3 compare ↓
Also priced by: Medicaid pays $0.8655/unit · Part D plans $0.6461/unit — full pricing hub ↓
Product page 60505-3275-03 Also comes in: 30 tablets 60505-3275-3 1000 tablets 60505-3275-8
Rx only Generic On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 8, 2026 · this listing last changed Oct 8, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

NDC database record

One package, one record: these facts belong to NDC 60505-3275-0 alone.

Record
FDA NDC Directory package listing · Human prescription drug
Code segments
60505 labeler · 3275 product · 0 package
Package marketed since
Oct 24, 2011
Sample package
No — commercial package
Listing certified through
Dec 31, 2027
Barcode (UPC-A, from the NDC)
3 6050532750 8
Medicaid fills, this package
1,704 prescriptions in the last four reported quarters
FDA record last changed
Oct 8, 2026
⚠️
Other active recalls for Olanzapine (different manufacturers) — 1 · tap to view
These affect other manufacturers’ products for the same ingredient — not necessarily the exact NDC on this page.
Class II · Nov 25, 2024 — Failed Impurities/Degradation Specifications (Macleods Pharmaceuticals Ltd) · FDA recall D-0154-2025
Each entry is an official FDA enforcement report — look up any recall number in the FDA recall database ↗

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 60505-3275-0
Product NDC 60505-3275
11-digit billing NDC 60505327500
NCPDP billing unit EA — each (per item)
Application # ANDA091265
SPL Set ID 938a4d2b-3654-0987-946f-3642bccb10c1
Established class (EPC) Atypical Antipsychotic
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2011-10-24
Route ORAL
Dosage form TABLET, ORALLY DISINTEGRATING
Substance OLANZAPINE
TE code (Orange Book) AB · RLD · RS

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GCN Seq No 045190
GCN 92007
HICL code 011814
Ingredient (HICL) Olanzapine
HIC1 code H
Therapeutic class — broad (HIC1) Nervous System (Except Autonomic)
HIC2 code H7
Therapeutic class — intermediate (HIC2) Psychoactive Drugs (Continued 1)
HIC3 code H7T
Therapeutic class — specific (HIC3) Antipsychotic,Atypical,Dopamine,Serotonin Antagnst
AHFS code 28:16.08.04
AHFS class Atypical Antipsychotics
FDB label name OLANZAPINE ODT 5 MG TABLET
FDB brand name Olanzapine Odt
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 045190
  • GCN: 92007
  • HICL (First Databank): 011814
  • AHFS class code: 28:16.08.04
Why two NDCs? The FDA registers this code as 60505-3275-0 — a 5-4-1 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the package segment → 60505-3275-00. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

Clinical

Label name OLANZAPINE ODT 5 MG TABLET Ingredient Olanzapine
📖 What it is MedlinePlus · NLM

Olanzapine is used to treat schizophrenia (a mental illness that affects how a person thinks, feels and behaves) and bipolar I disorder (a disease that causes depression, mania, and other abnormal moods). Olanzapine is in a class of medications called atypical antipsychotics. It works by changing the activity of certain natural substances in the brain.

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • It treats schizophrenia and manic or mixed episodes of bipolar I disorder, and can be added to lithium or valproate. An injection form is used for sudden agitation with those condi...
  • Oral olanzapine is usually taken once a day, with or without food. Take it as your prescriber directs and don’t stop on your own. Injections are given by a healthcare professional.
  • Sleepiness, dizziness, dry mouth, constipation, increased appetite and weight gain are common. Stand up slowly, especially at first. Your prescriber will check blood sugar, cholest...
  • Call right away for fever with stiff muscles or confusion, a severe rash, fainting, seizures, uncontrolled movements, extreme thirst or urination, or thoughts of self-harm.
📖 Read our full Olanzapine guide →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eaPer package
Retail pharmacies payNADAC · weekly $0.304 $30.36 / 100 tablets
Medicaid paysCMS SDUD · 12 mo $0.8655 $86.55 / 100 tablets
Medicare drug plans payPart D · Q2 2026 $0.6461 $64.61 / 100 tablets
NADAC price history (per ea) — tap or hover for the price & month
Jan 2022 Aug 2022 Jan 2026 Sep 2026 $0.592 $0.289
▼ Down 35% over the last 24 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startMarketing endStatus
60505-3275-00 You're viewing this 10 BLISTER PACK in 1 CARTON / 10 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK $0.3036 / ea $30.36 2011-10-24 — Active
60505-3275-03 60505-3275-3 Main listing 30 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE $0.3036 / ea $9.11 2011-10-24 — Active
60505-3275-08 60505-3275-8 1000 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE — — 2011-10-24 — Active

This pack has the lowest per-ea cost of the 2 priced pack sizes ($0.3036 NADAC).

This pack accounts for about 4.0% of this product's recent Medicaid fills; most go to the 30 tablets pack. See all packs ↓

Pack size FAQ

What quantity is in this package?
This package is listed by the FDA — 10 blister pack in 1 carton / 10 tablet, orally disintegrating in 1 blister pack.
What NDC number is used to bill for this package of Olanzapine 5 mg Tablet, Orally Disintegrating?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Olanzapine 5 mg 00093-5245-65 Teva 1 tablet $0.304 AB Availability likely —
Olanzapine 5 mg 33342-0083-07 Macleods 30 tablets $0.304 AB Availability likely —
Olanzapine 5 mg 55111-0262-79 Dr.Reddy's 10 tablets $0.304 AB Availability likely —
Olanzapine 5 mgthis 60505-3275-00 Apotex 10 tablets $0.304 AB Availability likely —
Olanzapine 5 mg 64380-0172-02 Strides 10 tablets $0.304 AB Availability likely —
Olanzapine 5 mg 72303-0841-01 HEC 30 tablets $0.304 AB Availability likely —
Olanzapine 5 mg 59746-0306-32 Jubilant 10 tablets $0.360 AB FDA listed +19%
Olanzapine 5 mg 65862-0656-03 Aurobindo 10 tablets $0.360 — FDA listed +19%
ZYPREXA Zydis 5 mg 00002-4453-85 Eli 1 tablet — AB Discontinued —
Olanzapine 5 mg 00527-3161-32 Lannett 30 tablets — AB FDA listed —
Olanzapine 5 mg 13668-0086-05 Torrent 500 tablets — AB FDA listed —
Olanzapine 5 mg 51407-0261-30 Golden 30 tablets — AB FDA listed —
ZYPREXA Zydis 5 mg 61269-0650-35 H2-Pharma 1 tablet — AB FDA listed —
Olanzapine 5 mg 63629-8717-01 Bryant 30 tablets — AB FDA listed —
Olanzapine 5 mg 67046-1550-03 Coupler 30 tablets — AB FDA listed —
olanzapine 5 mg 69452-0561-13 Bionpharma 30 tablets — AB FDA listed —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2011
On the market since
Oct 2011
📍
2026
Currently FDA-listed
15 years listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

🧪 Avoiding an ingredient? See Olanzapine inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.

Loading inactive ingredients from the official FDA label in the background. No external source is being called by this page request.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerApotex Corp.
Application holderAPOTEX INC
FDA applicationANDA091265 (ANDA)
Labeler code60505
First marketedOct 2011
Product typeHuman Prescription Drug
Portfolio313 products on file

More NDCs from Apotex Corp. labeler code 60505

The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
📄 FDA label
📄 FDA label 19 words ▾

No FDA label is on file for this product yet. Labels load from openFDA / DailyMed and refresh weekly.

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
1.7K
Units reimbursed last 4 qtrs
26.7K
Gross reimbursed last 4 qtrs
$23.1K
Avg / prescription
$13.56
Avg / unit
$0.8655
Latest quarter Q1 2026
206Rx
Medicaid pays / ea
$0.8655
gross reimbursed
vs
NADAC / ea
$0.3036
acquisition cost
=
Spread
+$0.5619
+185% vs cost
What Medicaid paid per ea (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
52% FFS 48% MCO
Fee-for-service · 878 Rx Managed care · 826 Rx
State Medicaid map
Alaska: 265 units · 36.2 per 100k residents AK Maine: no data reported ME Washington: 3,445 units · 44.1 per 100k residents WA Idaho: no data reported ID Montana: no data reported MT North Dakota: no data reported ND Minnesota: 173 units · 3.0 per 100k residents MN Wisconsin: no data reported WI Michigan: no data reported MI New York: 437 units · 2.2 per 100k residents NY Vermont: no data reported VT New Hampshire: 129 units · 9.2 per 100k residents NH Oregon: 939 units · 22.2 per 100k residents OR Nevada: no data reported NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: no data reported IA Illinois: no data reported IL Indiana: 53 units · 0.8 per 100k residents IN Ohio: 413 units · 3.5 per 100k residents OH Pennsylvania: no data reported PA New Jersey: no data reported NJ Massachusetts: 250 units · 3.6 per 100k residents MA California: 15,404 units · 39.5 per 100k residents CA Utah: no data reported UT Colorado: 230 units · 3.9 per 100k residents CO Nebraska: no data reported NE Missouri: 170 units · 2.7 per 100k residents MO Kentucky: 147 units · 3.2 per 100k residents KY West Virginia: no data reported WV Virginia: 463 units · 5.3 per 100k residents VA Maryland: no data reported MD Connecticut: no data reported CT Rhode Island: no data reported RI Arizona: 2,522 units · 33.9 per 100k residents AZ New Mexico: no data reported NM Kansas: no data reported KS Arkansas: no data reported AR Tennessee: no data reported TN North Carolina: 320 units · 3.0 per 100k residents NC South Carolina: no data reported SC Delaware: no data reported DE Oklahoma: no data reported OK Louisiana: no data reported LA Mississippi: 196 units · 6.7 per 100k residents MS Alabama: no data reported AL Georgia: no data reported GA D.C.: no data reported DC Hawaii: 30 units · 2.1 per 100k residents HI Texas: 1,108 units · 3.6 per 100k residents TX Florida: no data reported FL
Units reimbursed · per 100k residents
0.844.1
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Washington 44.1 /100k
2 California 39.5 /100k
3 Alaska 36.2 /100k
4 Arizona 33.9 /100k
5 Oregon 22.2 /100k
6 New Hampshire 9.2 /100k
7 Mississippi 6.7 /100k
8 Virginia 5.3 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
30 tablets60505-3275-03 41,069 Rx · $860,430
10 tablets this page60505-3275-00 1,704 Rx · $23,103
1000 tablets60505-3275-08 No Medicaid data
Drug total (last 4 qtrs): 42,773 Rx · 1,523,631 units · $883,533 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Olanzapine — the program that covers self-administered drugs. 17 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Olanzapine. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$25.57M
Claims incl. refills
939.5K
Beneficiaries
374.1K
Spend / beneficiary
$68.35
Spend / claim
$27.22
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.
← 60505-3252-03 · Apotex 60505-3276-00 · Apotex →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.